{"shortAnswer":"NAD+ is in Category 1: pharmacies may use it while FDA decides, which is not approval. The evidence grade is limited-human: one small heart trial and a few pilot studies. FDA has reports of harm after NAD+ drips and shots, and warns against food-grade NAD+.","url":"https://peptideindex.ai/compound/nad-plus","status":"category-1","statusCheckedAt":"2026-10-26T13:39:15.432Z","statusStale":false,"regulatoryAsOf":"2026-10-26","verified":"2026-10-26T13:39:15.470Z","primarySourceUrl":"https://www.fda.gov/media/94155/download","clinicallyReviewed":false,"notice":"Information, not medical advice.","id":"fc76b9c3-6c58-4e79-b2d1-1632524ddd1d","object":"compound","slug":"nad-plus","name":"NAD+","attrs":{"name":"NAD+","class":"non-peptide","access":[{"type":"lawful-compounding","detail":"A pharmacy may compound NAD+ on a prescription because it is in Category 1. A compounded product is not FDA-approved.","source_url":"https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act"},{"type":"clinical-trial","detail":"A trial in the US is recruiting healthy adults to compare NAD+ shots with a precursor. The trials block lists open trials.","source_url":"https://clinicaltrials.gov/study/NCT06919328"}],"trials":[{"nct":"NCT07839130","url":"https://clinicaltrials.gov/study/NCT07839130","phase":"Phase 2","title":"PEDIatric Cardiac Dysfunction Treated With Injectable Nicotinamide Adenine Dinucleotide","status":"not-yet-recruiting","sponsor":"Beijing Children's Hospital","countries":["China"],"us_states":[]},{"nct":"NCT07692633","url":"https://clinicaltrials.gov/study/NCT07692633","phase":"Not applicable","title":"A Clinical Trial to Assess the Absorption, Safety, and Efficacy of an Oral Nicotinamide Adenine Dinucleotide (NAD+) Supplement in Healthy Adults","status":"not-yet-recruiting","sponsor":"Reus Research","countries":["Canada"],"us_states":[]},{"nct":"NCT07328100","url":"https://clinicaltrials.gov/study/NCT07328100","phase":"Not applicable","title":"Efficacy and Safety of Coenzyme I for Injection on Vascular Aging.","status":"not-yet-recruiting","sponsor":"Shanghai 10th People's Hospital","countries":["China"],"us_states":[]},{"nct":"NCT06966583","url":"https://clinicaltrials.gov/study/NCT06966583","phase":"Phase 1","title":"NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC","status":"not-yet-recruiting","sponsor":"Sichuan University","countries":["China"],"us_states":[]},{"nct":"NCT06558253","url":"https://clinicaltrials.gov/study/NCT06558253","phase":"Phase 1","title":"The Safety and Efficacy of Coenzyme I for Injection in Promoting Hematopoietic Recovery of Patients After sUCBT","status":"recruiting","sponsor":"Anhui Provincial Hospital","countries":["China"],"us_states":[]},{"nct":"NCT06919328","url":"https://clinicaltrials.gov/study/NCT06919328","phase":"Not applicable","title":"Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+","status":"recruiting","sponsor":"Nutraceuticals Research Institute","countries":["United States"],"us_states":["Alabama"]}],"aliases":["NAD","nicotinamide adenine dinucleotide"],"summary":"A coenzyme, a helper molecule found in every living cell. It helps turn food into energy and repair DNA. Clinics offer it for health and longevity.","citations":[{"n":1,"url":"https://www.fda.gov/media/94155/download","tier":"primary","type":"regulatory","title":"FDA: 503A bulk drug substances category list, updated May 2026"},{"n":2,"url":"https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act","tier":"primary","type":"regulatory","title":"FDA: bulk drug substances used in compounding under section 503A"},{"n":3,"url":"https://www.fda.gov/media/94164/download","tier":"primary","type":"regulatory","title":"FDA: 503B bulk drug substances category list, updated March 2025"},{"n":4,"url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","tier":"primary","type":"regulatory","title":"FDA: bulk drug substances that may present significant safety risks"},{"n":5,"url":"https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding","tier":"primary","type":"regulatory","title":"FDA compounding alert: use ingredients suitable for sterile compounding, October 2024"},{"n":6,"url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/alive-nature-inc-607435-05062020","tier":"primary","type":"regulatory","title":"FDA and FTC warning letter: NAD+ and NMN gels sold with COVID-19 claims, May 2020"},{"n":7,"url":"https://www.fda.gov/food/dietary-supplements","tier":"primary","type":"regulatory","title":"FDA: dietary supplements"},{"n":8,"url":"https://www.fda.gov/food/dietary-supplements/new-dietary-ingredient-ndi-notification-process","tier":"primary","type":"regulatory","title":"FDA: new dietary ingredient notification process"},{"n":9,"url":"https://www.gfrlaw.com/what-we-do/insights/are-iv-businesses-compounding-prescriptions","tier":"legal-analysis","type":"legal-analysis","title":"Gordon Feinblatt: are IV businesses compounding prescriptions?"},{"n":10,"url":"https://pubmed.ncbi.nlm.nih.gov/31572171/","tier":"peer-reviewed","type":"human-trial","title":"Pilot study: NAD+ in blood and urine during a six-hour intravenous infusion in people, 2019"},{"n":11,"url":"https://pubmed.ncbi.nlm.nih.gov/41704678/","tier":"peer-reviewed","type":"human-trial","title":"Retrospective study: intravenous NAD+ compared with nicotinamide riboside, 2026"},{"n":12,"url":"https://pubmed.ncbi.nlm.nih.gov/40954388/","tier":"peer-reviewed","type":"rct","title":"Randomized trial: NAD+ in heart failure from ischemic cardiomyopathy, 2026"},{"n":13,"url":"https://pubmed.ncbi.nlm.nih.gov/10071523/","tier":"peer-reviewed","type":"human-trial","title":"Crossover trial: oral NADH in chronic fatigue syndrome, 1999"},{"n":14,"url":"https://pubmed.ncbi.nlm.nih.gov/41655607/","tier":"peer-reviewed","type":"systematic-review","title":"Systematic review: NAD+ supplementation for anti-aging and wellness, 2026"},{"n":15,"url":"https://pubmed.ncbi.nlm.nih.gov/38915015/","tier":"peer-reviewed","type":"systematic-review","title":"Meta-analysis: NAD+ precursor supplements, glucose, CRP and liver enzymes, 2024"},{"n":16,"url":"https://pubmed.ncbi.nlm.nih.gov/34497121/","tier":"peer-reviewed","type":"animal","title":"Mouse study: nicotinamide riboside, a precursor, in a model of Alzheimer's disease, 2021"},{"n":17,"url":"https://pubmed.ncbi.nlm.nih.gov/37395319/","tier":"peer-reviewed","type":"animal","title":"Mouse study: nicotinamide riboside, a precursor, and age-related hearing loss, 2023"},{"n":18,"url":"https://clinicaltrials.gov/study/NCT06919328","tier":"primary","type":"reference","title":"ClinicalTrials.gov NCT06919328: injected nicotinamide riboside compared with NAD+ in healthy adults"},{"n":19,"url":"https://clinicaltrials.gov/study/NCT07692633","tier":"primary","type":"reference","title":"ClinicalTrials.gov NCT07692633: an oral NAD+ supplement in healthy adults"},{"n":20,"url":"https://clinicaltrials.gov/study/NCT07839130","tier":"primary","type":"reference","title":"ClinicalTrials.gov NCT07839130: injectable NAD+ in children with cardiac dysfunction"},{"n":21,"url":"https://www.ajc.com/news/2026/07/tempted-to-try-a-wellness-or-longevity-treatment-heres-what-experts-say/","tier":"established-news","type":"reference","title":"Atlanta Journal-Constitution: what experts say about wellness and longevity treatments, July 2026"}],"known_risks":["FDA has reports of severe chills, shaking, vomiting and fatigue after NAD+ shots and drips. Some people needed medical care [^5].","FDA says these reactions fit too much endotoxin, a toxin from bacteria. Some products were made from food-grade NAD+, which is not fit for sterile drugs without proper processing [^5].","A 2026 study of clinic records looked at NAD+ drips. People had moderate to severe stomach upset, a faster heart rate and chest pressure [^11].","In the same review, the drips took longer because of these symptoms, and HDL, the good cholesterol, went down over 30 days [^11]."],"short_answer":"NAD+ is in Category 1: pharmacies may use it while FDA decides, which is not approval. The evidence grade is limited-human: one small heart trial and a few pilot studies. FDA has reports of harm after NAD+ drips and shots, and warns against food-grade NAD+.","evidence_grade":"limited-human","open_questions":["Nobody knows if NAD+ drips or shots slow aging or help wellness. A 2026 review found no outcome trials of them for those uses [^14].","NAD+ levels fall with age, but that does not show that taking NAD+ helps. Outcome trials have not tested it [^14] [^21].","It is not settled how much NAD+ taken by mouth reaches the blood. A trial in Canada plans to measure it [^19].","The one heart failure trial was small and at one hospital. Its authors call for larger trials at many centers [^12].","FDA has not yet decided whether to add NAD+ to the federal list for pharmacies [^1] [^2]."],"section_routes":"The legal ways to get NAD+ are from a pharmacy that compounds it, or in a clinical trial [^1] [^18].\n\nA prescriber can order NAD+ made by a pharmacy, because it is in Category 1 [^1] [^2]. That is not FDA approval [^2]. FDA has told compounders to use only ingredients fit for sterile drugs [^5].\n\nA trial in Alabama is recruiting healthy adults to compare NAD+ shots with a precursor [^18]. Other trials plan to start in Canada and China [^19] [^20]. The trials block on this page lists open trials with their dates.","regulatory_as_of":"2026-10-26","section_channels":"NAD+ drips and shots reach people through wellness clinics, med spas and drip bars [^11] [^21]. Some are made from food-grade NAD+ sold by repackagers [^5].\n\nFDA says food-grade ingredients are not fit for sterile drugs without proper processing [^5]. FDA has reports of severe chills, shaking, vomiting and fatigue after NAD+ shots and drips [^5]. FDA says these fit too much endotoxin, a toxin from bacteria [^5].\n\nUnder section 503A, a licensed pharmacist or doctor compounds, using ingredients that meet FDA's conditions [^2]. A law firm notes that FDA treats adding vitamins to a drip bag as compounding [^9].\n\nAn online seller marketed NAD+ gels with disease claims. In 2020, FDA and the FTC warned that seller over COVID-19 claims [^6].","section_evidence":"The evidence grade is limited-human: one randomized trial and a few small studies test NAD+ itself, and none test aging [^12] [^14].\n\nHeart failure: in a trial in China, 180 adults with heart failure got NAD+ or a dummy drip for a week [^12]. At one month, heart pumping improved a little more with NAD+ [^12]. Hospital stays and symptoms showed only trends, not clear results [^12].\n\nDrips in people: a 2019 pilot in people tracked NAD+ in the blood during a six-hour drip [^10]. It measured levels, not health [^10]. A 2026 review of clinic records found NAD+ drips caused more discomfort than drips of a precursor [^11].\n\nNADH: a 1999 crossover trial of 26 people with chronic fatigue syndrome tested NADH pills, the reduced form [^13]. Eight improved on NADH and two on a dummy pill [^13]. That is a small result for a related form [^13].\n\nAging: a 2026 systematic review found no outcome trials of NAD+ drips or shots for aging or wellness [^14]. Precursor pills raised NAD+ levels, but health results were mixed or null [^14].\n\nAnimals: mouse studies often cited for NAD+ used nicotinamide riboside, a precursor [^16] [^17]. In mice, it slowed hearing loss with age and eased signs of an Alzheimer's model [^16] [^17]. Those are precursor results in mice, not NAD+ results in people [^16] [^17].","regulatory_status":"category-1","section_what_it_is":"NAD+ is short for nicotinamide adenine dinucleotide. It is a coenzyme, a helper molecule found in every living cell [^21]. Cells use it to turn food into energy and to repair DNA [^21]. It is not a peptide. NADH is its reduced form, and FDA lists the two apart [^1].\n\nIt is sold in several forms. Clinics give it by drip into a vein or by shot [^5] [^11]. Pills and gels held under the tongue are sold too [^6] [^19]. A result for one form does not carry over to another [^14].\n\nMany studies use precursors instead, such as nicotinamide riboside (NR) or NMN. The body turns these into NAD+, but they are different compounds [^14] [^15]. A study of a precursor is not a study of NAD+ [^14].","section_is_it_legal":"NAD+ is in Category 1: FDA's list of substances pharmacies may use while FDA decides whether to add them to the federal list [^1] [^2]. That is not approval, and FDA is still deciding [^1] [^2]. Checked 26 October 2026.\n\nFDA's May 2026 list names NAD and NADH under Category 1 [^1]. One salt form is in Category 3, which falls outside FDA's policy for Category 1 [^1] [^2]. For Category 1, FDA says it does not plan to act against a pharmacy that meets the policy's conditions [^2]. That is a choice not to act, not approval of NAD+ as a drug [^2]. NAD+ is also in Category 1 on FDA's list for outsourcing facilities, which make larger batches [^3]. It is not in Category 2, FDA's list of substances that may present significant safety risks [^1] [^4].\n\nIn 2020, FDA and the FTC warned a seller of NAD+ gels sold with COVID-19 claims. FDA called those gels unapproved new drugs [^6]. Pills and gels are often called supplements [^19] [^21]. No FDA page we checked names NAD+ as a dietary supplement ingredient [^7] [^8]. So this page does not give it that status.","unofficial_channels":[{"type":"compounding-outside-the-rules","what_it_is":"NAD+ drips and shots made from food-grade NAD+ sold by repackagers, which is not meant for sterile drugs.","enforcement":[{"date":"2024-10-30","text":"FDA compounding alert: compounders used food-grade NAD+ to make drips; FDA reminded them to use ingredients fit for sterile drugs.","source_url":"https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding"}],"legal_position":{"text":"FDA says food-grade ingredients are not fit for compounding sterile drugs without proper processing.","source_url":"https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding"},"documented_risks":[{"text":"FDA has reports of severe chills, shaking, vomiting and fatigue after NAD+ shots and drips. Some people needed medical care.","source_url":"https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding"}]},{"type":"clinic-or-med-spa","what_it_is":"Wellness clinics, med spas and drip bars that give NAD+ by drip into a vein, often for aging or energy.","legal_position":{"text":"FDA does not plan to act against a licensed pharmacist or doctor who compounds with NAD+ under its Category 1 conditions. That is not approval.","source_url":"https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act"},"documented_risks":[{"text":"In a review of clinic records, people given NAD+ by drip had moderate to severe stomach upset, a faster heart rate and chest pressure.","source_url":"https://pubmed.ncbi.nlm.nih.gov/41704678/"}]}]},"provenance":{"name":{"fact_id":"bf82c68e-56ac-4f2d-9b58-a80ad8b9fb17","source_url":"https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding","source_type":"primary","captured_at":"2026-10-26T10:18:56.154Z","checked_at":"2026-10-26T13:39:15.448Z","confidence":1,"stale":false},"class":{"fact_id":"b817c175-c2f7-4e47-8e60-2ee40ac13cd6","source_url":"https://pubmed.ncbi.nlm.nih.gov/31572171/","source_type":"peer-reviewed","captured_at":"2026-10-26T10:19:47.096Z","checked_at":"2026-10-26T13:39:15.452Z","confidence":1,"stale":false},"access":{"fact_id":"22b48aaa-a20d-4111-b999-bd5726406df6","source_url":"https://www.fda.gov/media/94155/download","source_type":"primary","captured_at":"2026-10-26T06:06:47.298Z","checked_at":"2026-10-26T13:39:15.411Z","confidence":1,"stale":false},"trials":{"fact_id":"c2664202-3222-4d3a-acb0-7597cde024a4","source_url":"https://clinicaltrials.gov/api/v2/studies?query.intr=AREA%5BInterventionName%5D%28%22NAD%2B%22+OR+%22Nicotinamide+Adenine+Dinucleotide%22+OR+%22Coenzyme+I%22%29+AND+NOT+AREA%5BInterventionName%5D%28precursor+OR+NMN+OR+mononucleotide%29&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING&pageSize=50&sort=StartDate%3Adesc&countTotal=true&fields=NCTId%2CBriefTitle%2COverallStatus%2CPhase%2CLeadSponsorName%2CStartDate%2CLocationCountry%2CLocationState","source_type":"primary","captured_at":"2026-10-26T13:39:42.127Z","checked_at":"2026-10-26T13:39:42.127Z","confidence":1,"stale":false},"aliases":{"fact_id":"95b14fbb-ba5a-43be-b9d2-bb571c3b9412","source_url":"https://www.fda.gov/media/94155/download","source_type":"primary","captured_at":"2026-10-26T06:06:47.298Z","checked_at":"2026-10-26T13:39:15.450Z","confidence":1,"stale":false},"summary":{"fact_id":"c8c96ba3-89cb-4138-839c-849af755931f","source_url":"https://www.ajc.com/news/2026/07/tempted-to-try-a-wellness-or-longevity-treatment-heres-what-experts-say/","source_type":"established-news","captured_at":"2026-10-26T10:18:59.117Z","checked_at":"2026-10-26T13:39:15.455Z","confidence":1,"stale":false},"citations":{"fact_id":"c8a58259-be03-42ab-89a6-f1ae25328ae9","source_url":"https://www.fda.gov/media/94155/download","source_type":"primary","captured_at":"2026-10-26T06:06:47.298Z","checked_at":"2026-10-26T13:39:15.470Z","confidence":1,"stale":false},"known_risks":{"fact_id":"18c75a80-ebdc-465e-ae38-9adfcdbb4ed3","source_url":"https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding","source_type":"primary","captured_at":"2026-10-26T10:18:56.154Z","checked_at":"2026-10-26T13:39:15.425Z","confidence":1,"stale":false},"short_answer":{"fact_id":"3ce13883-2adc-4f03-8257-8381e0c062ba","source_url":"https://peptideindex.ai/methodology#short-answer","source_type":"reference","captured_at":"2026-10-25T00:14:44.418Z","checked_at":"2026-10-26T13:39:15.439Z","confidence":1,"stale":false,"label":"our assessment"},"evidence_grade":{"fact_id":"bab40984-ef07-491d-a6d0-6c9ef54fce9b","source_url":"https://peptideindex.ai/methodology#evidence-grade","source_type":"reference","captured_at":"2026-10-25T00:14:45.193Z","checked_at":"2026-10-26T13:39:15.418Z","confidence":1,"stale":false,"label":"our assessment"},"open_questions":{"fact_id":"3ea68a87-c17e-4648-a290-851b45443886","source_url":"https://pubmed.ncbi.nlm.nih.gov/41655607/","source_type":"peer-reviewed","captured_at":"2026-10-26T10:19:50.845Z","checked_at":"2026-10-26T13:39:15.457Z","confidence":1,"stale":false},"section_routes":{"fact_id":"61e7b83d-5915-462d-a720-713342353e3d","source_url":"https://www.fda.gov/media/94155/download","source_type":"primary","captured_at":"2026-10-26T06:06:47.298Z","checked_at":"2026-10-26T13:39:15.466Z","confidence":1,"stale":false},"regulatory_as_of":{"fact_id":"ec60239c-2f03-4cf8-bd7f-24f0313e1e59","source_url":"https://www.fda.gov/media/94155/download","source_type":"primary","captured_at":"2026-10-26T06:06:47.298Z","checked_at":"2026-10-26T13:39:15.429Z","confidence":1,"stale":false},"section_channels":{"fact_id":"d3cbc25b-538e-4d62-b0bd-251b7d702080","source_url":"https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding","source_type":"primary","captured_at":"2026-10-26T10:18:56.154Z","checked_at":"2026-10-26T13:39:15.434Z","confidence":1,"stale":false},"section_evidence":{"fact_id":"260e4de4-f5b5-4374-8029-df5559620ccf","source_url":"https://pubmed.ncbi.nlm.nih.gov/40954388/","source_type":"peer-reviewed","captured_at":"2026-10-26T10:19:50.098Z","checked_at":"2026-10-26T13:39:15.464Z","confidence":1,"stale":false},"regulatory_status":{"fact_id":"86686101-3d7b-46ad-96f3-fdf83d3f2403","source_url":"https://www.fda.gov/media/94155/download","source_type":"primary","captured_at":"2026-10-26T06:06:47.298Z","checked_at":"2026-10-26T13:39:15.432Z","confidence":1,"stale":false},"section_what_it_is":{"fact_id":"4e5bcdfc-ecf2-4b20-862f-167fee4cb415","source_url":"https://www.fda.gov/media/94155/download","source_type":"primary","captured_at":"2026-10-26T06:06:47.298Z","checked_at":"2026-10-26T13:39:15.459Z","confidence":1,"stale":false},"section_is_it_legal":{"fact_id":"b31f9eea-064f-4c90-bfee-7b5f09b11e4c","source_url":"https://www.fda.gov/media/94155/download","source_type":"primary","captured_at":"2026-10-26T06:06:47.298Z","checked_at":"2026-10-26T13:39:15.462Z","confidence":1,"stale":false},"unofficial_channels":{"fact_id":"ec5e1ebd-20a6-41c8-90a5-c68b677cc505","source_url":"https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding","source_type":"primary","captured_at":"2026-10-26T10:18:56.154Z","checked_at":"2026-10-26T13:39:15.444Z","confidence":1,"stale":false}},"citationsBySection":{"known_risks":[{"n":5,"title":"FDA compounding alert: use ingredients suitable for sterile compounding, October 2024","url":"https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding"},{"n":11,"title":"Retrospective study: intravenous NAD+ compared with nicotinamide riboside, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/41704678/"}],"open_questions":[{"n":14,"title":"Systematic review: NAD+ supplementation for anti-aging and wellness, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/41655607/"},{"n":21,"title":"Atlanta Journal-Constitution: what experts say about wellness and longevity treatments, July 2026","url":"https://www.ajc.com/news/2026/07/tempted-to-try-a-wellness-or-longevity-treatment-heres-what-experts-say/"},{"n":19,"title":"ClinicalTrials.gov NCT07692633: an oral NAD+ supplement in healthy adults","url":"https://clinicaltrials.gov/study/NCT07692633"},{"n":12,"title":"Randomized trial: NAD+ in heart failure from ischemic cardiomyopathy, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/40954388/"},{"n":1,"title":"FDA: 503A bulk drug substances category list, updated May 2026","url":"https://www.fda.gov/media/94155/download"},{"n":2,"title":"FDA: bulk drug substances used in compounding under section 503A","url":"https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act"}],"section_routes":[{"n":1,"title":"FDA: 503A bulk drug substances category list, updated May 2026","url":"https://www.fda.gov/media/94155/download"},{"n":18,"title":"ClinicalTrials.gov NCT06919328: injected nicotinamide riboside compared with NAD+ in healthy adults","url":"https://clinicaltrials.gov/study/NCT06919328"},{"n":2,"title":"FDA: bulk drug substances used in compounding under section 503A","url":"https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act"},{"n":5,"title":"FDA compounding alert: use ingredients suitable for sterile compounding, October 2024","url":"https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding"},{"n":19,"title":"ClinicalTrials.gov NCT07692633: an oral NAD+ supplement in healthy adults","url":"https://clinicaltrials.gov/study/NCT07692633"},{"n":20,"title":"ClinicalTrials.gov NCT07839130: injectable NAD+ in children with cardiac dysfunction","url":"https://clinicaltrials.gov/study/NCT07839130"}],"section_channels":[{"n":11,"title":"Retrospective study: intravenous NAD+ compared with nicotinamide riboside, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/41704678/"},{"n":21,"title":"Atlanta Journal-Constitution: what experts say about wellness and longevity treatments, July 2026","url":"https://www.ajc.com/news/2026/07/tempted-to-try-a-wellness-or-longevity-treatment-heres-what-experts-say/"},{"n":5,"title":"FDA compounding alert: use ingredients suitable for sterile compounding, October 2024","url":"https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding"},{"n":2,"title":"FDA: bulk drug substances used in compounding under section 503A","url":"https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act"},{"n":9,"title":"Gordon Feinblatt: are IV businesses compounding prescriptions?","url":"https://www.gfrlaw.com/what-we-do/insights/are-iv-businesses-compounding-prescriptions"},{"n":6,"title":"FDA and FTC warning letter: NAD+ and NMN gels sold with COVID-19 claims, May 2020","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/alive-nature-inc-607435-05062020"}],"section_evidence":[{"n":12,"title":"Randomized trial: NAD+ in heart failure from ischemic cardiomyopathy, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/40954388/"},{"n":14,"title":"Systematic review: NAD+ supplementation for anti-aging and wellness, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/41655607/"},{"n":10,"title":"Pilot study: NAD+ in blood and urine during a six-hour intravenous infusion in people, 2019","url":"https://pubmed.ncbi.nlm.nih.gov/31572171/"},{"n":11,"title":"Retrospective study: intravenous NAD+ compared with nicotinamide riboside, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/41704678/"},{"n":13,"title":"Crossover trial: oral NADH in chronic fatigue syndrome, 1999","url":"https://pubmed.ncbi.nlm.nih.gov/10071523/"},{"n":16,"title":"Mouse study: nicotinamide riboside, a precursor, in a model of Alzheimer's disease, 2021","url":"https://pubmed.ncbi.nlm.nih.gov/34497121/"},{"n":17,"title":"Mouse study: nicotinamide riboside, a precursor, and age-related hearing loss, 2023","url":"https://pubmed.ncbi.nlm.nih.gov/37395319/"}],"section_what_it_is":[{"n":21,"title":"Atlanta Journal-Constitution: what experts say about wellness and longevity treatments, July 2026","url":"https://www.ajc.com/news/2026/07/tempted-to-try-a-wellness-or-longevity-treatment-heres-what-experts-say/"},{"n":1,"title":"FDA: 503A bulk drug substances category list, updated May 2026","url":"https://www.fda.gov/media/94155/download"},{"n":5,"title":"FDA compounding alert: use ingredients suitable for sterile compounding, October 2024","url":"https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding"},{"n":11,"title":"Retrospective study: intravenous NAD+ compared with nicotinamide riboside, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/41704678/"},{"n":6,"title":"FDA and FTC warning letter: NAD+ and NMN gels sold with COVID-19 claims, May 2020","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/alive-nature-inc-607435-05062020"},{"n":19,"title":"ClinicalTrials.gov NCT07692633: an oral NAD+ supplement in healthy adults","url":"https://clinicaltrials.gov/study/NCT07692633"},{"n":14,"title":"Systematic review: NAD+ supplementation for anti-aging and wellness, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/41655607/"},{"n":15,"title":"Meta-analysis: NAD+ precursor supplements, glucose, CRP and liver enzymes, 2024","url":"https://pubmed.ncbi.nlm.nih.gov/38915015/"}],"section_is_it_legal":[{"n":1,"title":"FDA: 503A bulk drug substances category list, updated May 2026","url":"https://www.fda.gov/media/94155/download"},{"n":2,"title":"FDA: bulk drug substances used in compounding under section 503A","url":"https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act"},{"n":3,"title":"FDA: 503B bulk drug substances category list, updated March 2025","url":"https://www.fda.gov/media/94164/download"},{"n":4,"title":"FDA: bulk drug substances that may present significant safety risks","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"n":6,"title":"FDA and FTC warning letter: NAD+ and NMN gels sold with COVID-19 claims, May 2020","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/alive-nature-inc-607435-05062020"},{"n":19,"title":"ClinicalTrials.gov NCT07692633: an oral NAD+ supplement in healthy adults","url":"https://clinicaltrials.gov/study/NCT07692633"},{"n":21,"title":"Atlanta Journal-Constitution: what experts say about wellness and longevity treatments, July 2026","url":"https://www.ajc.com/news/2026/07/tempted-to-try-a-wellness-or-longevity-treatment-heres-what-experts-say/"},{"n":7,"title":"FDA: dietary supplements","url":"https://www.fda.gov/food/dietary-supplements"},{"n":8,"title":"FDA: new dietary ingredient notification process","url":"https://www.fda.gov/food/dietary-supplements/new-dietary-ingredient-ndi-notification-process"}]},"channelsOpener":"This section describes what happens and is not a recommendation.","sources":["https://clinicaltrials.gov/api/v2/studies?query.intr=AREA%5BInterventionName%5D%28%22NAD%2B%22+OR+%22Nicotinamide+Adenine+Dinucleotide%22+OR+%22Coenzyme+I%22%29+AND+NOT+AREA%5BInterventionName%5D%28precursor+OR+NMN+OR+mononucleotide%29&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING&pageSize=50&sort=StartDate%3Adesc&countTotal=true&fields=NCTId%2CBriefTitle%2COverallStatus%2CPhase%2CLeadSponsorName%2CStartDate%2CLocationCountry%2CLocationState","https://peptideindex.ai/methodology#evidence-grade","https://peptideindex.ai/methodology#short-answer","https://pubmed.ncbi.nlm.nih.gov/31572171/","https://pubmed.ncbi.nlm.nih.gov/40954388/","https://pubmed.ncbi.nlm.nih.gov/41655607/","https://www.ajc.com/news/2026/07/tempted-to-try-a-wellness-or-longevity-treatment-heres-what-experts-say/","https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding","https://www.fda.gov/media/94155/download"],"verified_at":"2026-10-26T13:39:15.470Z","published_at":"2026-10-26T13:49:31.210Z","parent":null,"children":[],"snapshots":{"trials":{"snapshot_at":"2026-10-26T13:39:42.127Z","stale":false,"notice":"A listing is not a recommendation. Trials have strict eligibility rules. Talk to your doctor and read the official record."}}}